002262.SZ
Jiangsu Nhwa Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 21.27
−0.89%Year over year
Reported trailing growth
- Revenue
- +2.7%
- EBITDA
- —
- EBIT
- -11.1%
- EPS
- -9.7%
- Free cash flow
- -13.0%
- Operating cash flow
- -8.5%
Forward estimates
Based on analyst estimates
- Revenue
- +14.3%
- EBITDA
- +19.6%
- EPS
- +17.5%
Three-year CAGR
- Revenue
- +11.2%
- EBITDA
- +8.3%
- EBIT
- +6.1%
- Net income
- +5.5%
- EPS
- +5.7%
- Free cash flow
- +6.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026